brain
No description yet: the sentence for this tag has not been written. 9 records carry it: 9 people.
9 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Andrew B. Lassman Chief of Neuro-Oncology, Columbia University Irving Medical Center · Herbert Irving Comprehensive Cancer Center, Columbia University New York neuro-oncologist who led INTELLANCE-1, the trial that tested the EGFR-directed antibody-drug conjugate depatuxizumab mafodotin in newly diagnosed glioblastoma and found it did not extend survival. | Glioma & glioblastoma, Brain and spinal cord tumours | none | trialist | ||
Darren R. Hargrave Paediatric neuro-oncologist, Great Ormond Street Hospital and UCL Great Ormond Street Institute of Child Health · Great Ormond Street Hospital for Children London paediatric neuro-oncologist who led the trial showing that dabrafenib and trametinib work in children with BRAF V600-mutant high-grade glioma. | Paediatric high-grade glioma, Childhood cancers | none | paediatric, targeted-therapy, trialist | ||
Giles W. Robinson Paediatric neuro-oncologist, St. Jude Children's Research Hospital · St. Jude Children's Research Hospital Memphis paediatric neuro-oncologist who led the study showing that the Hedgehog inhibitor vismodegib helps only adults and older children whose medulloblastoma belongs to the SHH subgroup, an early example of subgroup-directed brain tumour therapy. | SHH-activated medulloblastoma, Medulloblastoma, Childhood cancers | none | paediatric, targeted-therapy, trialist | ||
Jacques Grill Paediatric neuro-oncologist, Gustave Roussy · Gustave Roussy Paris paediatric neuro-oncologist who led HERBY, the trial that showed adding bevacizumab does not help children with high-grade glioma, and who leads European trials in diffuse midline glioma. | Paediatric high-grade glioma, Glioma & glioblastoma, Childhood cancers | none | paediatric, trialist | ||
Jan C. Buckner Medical oncologist, Mayo Clinic · Mayo Clinic Mayo Clinic neuro-oncologist who was lead author of the long-term RTOG 9802 results, which showed that adding PCV chemotherapy to radiotherapy roughly doubles survival in high-risk low-grade glioma. | Astrocytoma, IDH-mutant, Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, Brain and spinal cord tumours | none | trialist | ||
Olivier L. Chinot Neuro-oncologist, Aix-Marseille University and Hôpital de la Timone · Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille Marseille neuro-oncologist who was lead author of AVAglio, the trial that showed adding bevacizumab to standard glioblastoma treatment delays progression but does not lengthen life. | Glioma & glioblastoma, Brain and spinal cord tumours | none | trialist | ||
Paul D. Brown Radiation oncologist, Mayo Clinic · Mayo Clinic Mayo Clinic radiation oncologist whose trials showed that focused radiosurgery preserves thinking and memory better than whole-brain radiotherapy for brain metastases, and that sparing the hippocampus reduces cognitive harm when whole-brain treatment is needed. | Brain metastases, Brain and spinal cord tumours | none | radiotherapy, trialist | ||
Sarah E. S. Leary Paediatric neuro-oncologist, Seattle Children's Hospital · Seattle Children's Hospital Seattle paediatric neuro-oncologist who led COG ACNS0332, the trial that found adding carboplatin to radiotherapy improves survival in children with high-risk group 3 medulloblastoma but isotretinoin does not help. | Group 3 and group 4 medulloblastoma, Medulloblastoma, Childhood cancers | none | paediatric, trialist | ||
Scott R. Plotkin Neuro-oncologist and Director of the Family Center for Neurofibromatosis, Massachusetts General Hospital · Massachusetts General Hospital Cancer Center Boston neuro-oncologist who showed that bevacizumab can shrink vestibular schwannomas and restore hearing in people with neurofibromatosis type 2. | Vestibular schwannoma, Brain and spinal cord tumours | none | rare-cancers, trialist |